FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-028								

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OIVID AFFROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Name and Address of Reporting Person* Moore Terrence O				<u> </u>	2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specifications)				ner
(Last) (First) (Middle) C/O ACADIA PHARMACEUTICALS INC. 3911 SORRENTO VALLEY BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 08/19/2013								X Office (give title Office) below) EVP, CHIEF COMMERCIAL OFFICER				
(Street) SAN DII		A tate)	92121 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. I	e) <mark>X</mark> Form fil	or Joint/Group Filing (Check Applicable rm filed by One Reporting Person rm filed by More than One Reporting rson				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				. Transactio ate Month/Day/	Execution Date		Transaction Dispose Code (Instr.		4. Securi Disposed	rities Acquired (A) o ed Of (D) (Instr. 3, 4		5. Amoun Securities Beneficia Owned Fo	Forn lly (D) o ollowing (I) (II		Direct I Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)			msu. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares	r	(Instr. 4)	J.1(3)		
Stock Option (right to buy)	\$19.61	08/19/2013		A		150,000		(1)	0	8/18/2023	Common Stock	150,000	\$0	150,00	00	D	

Explanation of Responses:

1. 25% of the shares subject to the Stock Option vest and become exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

/s/ Glenn F. Baity, Attorney-in-

08/20/2013

Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.